| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -33.38 | 21.76 | 28.25 | 1.95 |
Op profit growth | -28.27 | 28.23 | 12.86 | 7.88 |
EBIT growth | -30.49 | 34.04 | 5.98 | 18.08 |
Net profit growth | -6.94 | 39.73 | 11.66 | 46.91 |
Profitability ratios (%) | ||||
OPM | 22.89 | 21.26 | 20.19 | 22.95 |
EBIT margin | 17.46 | 16.74 | 15.2 | 18.4 |
Net profit margin | 13.7 | 9.81 | 8.55 | 9.82 |
RoCE | 11.51 | 16.71 | 14.95 | 14.15 |
RoNW | 4.03 | 4.63 | 4.27 | 4.49 |
RoA | 2.25 | 2.44 | 2.1 | 1.88 |
Per share ratios (₹) | ||||
EPS | 52.49 | 56.39 | 40.72 | 36.89 |
Dividend per share | 5 | 5 | 3 | 3 |
Cash EPS | 30.56 | 27.38 | 14.61 | 18.25 |
Book value per share | 297.64 | 351.77 | 262.3 | 220.61 |
Valuation ratios | ||||
P/E | 12.96 | 3.82 | 17.89 | 18.78 |
P/CEPS | 22.25 | 7.88 | 49.84 | 37.96 |
P/B | 2.28 | 0.61 | 2.77 | 3.14 |
EV/EBIDTA | 9.19 | 3.69 | 10.65 | 11.9 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 7.26 | 8.11 |
Tax payout | -33.73 | -25.07 | -26.15 | -22.09 |
Liquidity ratios | ||||
Debtor days | 63.23 | 48.32 | 51.85 | 60.89 |
Inventory days | 89.02 | 64.52 | 63.4 | 75.45 |
Creditor days | -65.15 | -58.27 | -59.85 | -57.53 |
Leverage ratios | ||||
Interest coverage | -5.78 | -5.33 | -4.02 | -3.16 |
Net debt / equity | 0.45 | 0.6 | 0.78 | 1.04 |
Net debt / op. profit | 1.54 | 1.75 | 2.12 | 2.66 |
Cost breakup (₹) | ||||
Material costs | -25.18 | -34.3 | -38.15 | -34.11 |
Employee costs | -31.53 | -23.24 | -20.69 | -21 |
Other costs | -20.38 | -21.18 | -20.94 | -21.93 |
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
